Procalcitonin and proinflammatory cytokine interactions in sepsis (vol 12,pg 268, 1999)

Citation
Kt. Whang et al., Procalcitonin and proinflammatory cytokine interactions in sepsis (vol 12,pg 268, 1999), SHOCK, 14(1), 2000, pp. 73-78
Citations number
32
Categorie Soggetti
Cardiovascular & Hematology Research
Journal title
SHOCK
ISSN journal
10732322 → ACNP
Volume
14
Issue
1
Year of publication
2000
Pages
73 - 78
Database
ISI
SICI code
1073-2322(200007)14:1<73:PAPCII>2.0.ZU;2-Z
Abstract
Immunoneutralization of procalcitonin (ProCT), a putative mediator of sepsi s, has been shown to increase survival in an animal model of sepsis. To bet ter understand the role that ProCT plays in the sepsis cascade, we studied the relationship of this hormone to the proximal proinflammatory mediators, IL-1 beta and TNF alpha. Hamsters were made septic by i.p. implantation of Escherichia coli-impregnated agar pellets. A time line study of serum IL-b eta, TNF alpha, and ProCT levels showed that the increase in the cytokines was transient and less than e-fold over baseline, whereas ProCT increased > 100-fold by 12 h and remains elevated through 24 h. TNF alpha (400 mu g/kg) was injected into healthy animals, inducing an elevation in ProCT that was 25-fold greater than controls. ProCT (30 mu g/kg) was given to healthy and septic animals. In healthy animals, there was no significant elevation in serum IL-1 beta or TNF alpha levels. In septic animals, IL-1 beta was modes tly blunted at 3 h but not at 12 h, and there was no change in TNF alpha le vels. ProCT did not initiate or enhance IL-1 beta or TNF alpha expression; however, the massive and sustained elevation of this hormone seen in sepsis can be induced by the proximal cytokine, TNF alpha. This study suggests th at ProCT is a secondary mediator that might augment and amplify but does no t initiate the septic response. Immunoneutralization of ProCT may prove to be an important clinical strategy, in view of its sustained elevation and t he difficulty in initiating therapy for sepsis during the early phases of i llness.